Searched for
RAKESH BAMZAI
Mylan wants to capture chronic Hep B marketThe drug was approved in India in November this year and is the “first” to be approved in eight years for the management of this infection ...
08 Dec, 2017, 09.45 PM IST
Biocon posts 15% rise in revenue, names new CEOBiocon, the country's largest biotech company, reported a 15% rise in fourth-quarter revenue to 746 crore, helped by a 17% rise in sales at...
26 Apr, 2014, 04.59 AM IST
Pricing of imported drugs under regulatory scannerNPPA has initiated a process to end the freedom enjoyed by drug makers to fix the retail price of their imported medicines.
06 Sep, 2012, 09.07 AM IST
- Biocon Q4 net up 25.04% at Rs 101 cr, to hire 1,000
Biocon Ltd reported a 25 percent rise in fourth-quarter profit as strong sales of its biopharmaceutical drugs helped offset muted sales at ...
28 Apr, 2011, 02.48 PM IST
- Biocon seals Rs 1,550 cr pact with Pfizer
The agreement includes the commercialisation of Biocon’s biosimilar versions of insulin and insulin analog products: recombinant human insu...
19 Oct, 2010, 12.26 AM IST
- Wockhardt, Biocon under NPPA scanner
Wockhardt and Biocon have come under the drug price regulator National Pharmaceutical Pricing Authority (NPPA) scanner for allegedly violat...
29 Jun, 2009, 04.53 AM IST
- Biocon launches breast cancer drug
Biotech company Biocon said it has launched the drug Abraxane, used in the treatment of breast cancer.
18 Jul, 2008, 08.16 PM IST
- Biocon forays into nephrology space
The new immunosuppressants for renal therapy are at least 35-40 per cent cheaper than the MNC drug prices in the similar product category.
08 Mar, 2007, 05.10 PM IST